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Abstract
Amitraz (AM) and romifidine (RMF), two alpha-2 adrenoceptor
agonists, produce sedative effect and decrease spontaneous locomotor
activity (SLA) of horses. The behavioral effects and sedation after
intravenous injection of RMF (0.06mg/kg) or AM 0.1mg/kg (AM
0.1) or AM 0.4mg/kg (AM 0.4) were compared in horses. RMF caused
head ptosis (HP) until 45 min. The lower AM dose induced HP from
45 to 60 minutes and from 120 to 150 minutes, and the higher dose
induced HP until 180 minutes. Data concerning changes in SLA were
not conclusive. RMF or AM 0.4 caused a greater sedation than AM 0.1
until 20 min. After 20 minutes, the sedation caused by AM 0.4 was
greater than that of RMF or AM 0.1. Romifidine caused consistent
sedation until 45 minutes. The amitraz emulsion produced a dose-
dependent sedation until 180 minutes. Comparing to romifidine,
the emulsion of amitraz induced a more substantial sedation. At









Restraining horses in small rooms
stimulates exploratory behaviors that can be
defined as spontaneous locomotor activity.1
Tobin et al. 2 developed a study method on
behavioral stalls in order to measure the
effects of stimulant or sedative substances
on the spontaneous locomotor activity of
horses, which was improved by Kamerling
et al. 3.
The sedative effects of alpha-2
adrenoceptor agonists on horses include
bradypnea, head ptosis, dropping of the
upper eyelids and of  the lower lip, ataxia
and also penis exposition. Frequently,
hypertension occurs because of increased
peripheral vascular resistance and
subsequently bradycardia, hypotension and
decrease of  cardiac output 4,5 are observed.
Drugs from this group have affinity and
specificity for subtypes of alpha-2 receptors
that grant them diverse extent of effects,
intensity of sedation and analgesia.6
Romifidine, as xylazine and
detomidine, is an alpha-2 adrenoceptor
agonist that produces cardiovascular changes
7, including bradycardia, second-degree
atrioventricular block and hypertension
followed by hypotension8.  In horses,
romifidine at doses varying from 0.4 to
1 mg/kg induces dose-dependent sedation.9,10,11
Amitraz showed central effects of
alpha-2 adrenoceptor agonist, inducing
similar ataxia, intestinal stasis, behavioral,
cardiovascular, muscular and diuretic
effects.12,13,14,15,16,17 These effects could provide
an indication for the use of amitraz for
sedation practices in veterinary medicine, and
this might be particularly appealing in horses
because of its low price and its potential
analgesic and muscle relaxing effects.18
Considering the well known effects
of romifidine on horses, mediated by its
highly specific action on alpha-2
adrenoceptors, this behavioral study
proposes to compare its sedative effects with
those induced by an emulsion of amitraz, in
order to determine the possibility of  using
this drug as a sedative for horses.
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Material and Method
Six adult, male horses, between three
and ten years of age were used, all in good
clinical conditions and not exposed to amitraz
for at least six months. During the adaptation
period, horses were fed a commercial diet
twice a day, water and grass hay ad libitum
and conditioned to the behavioral stalls. Each
horse was submitted to all treatments in time
intervals of  at least 15 days. Thus each animal
was considered as a control of itself, which
configures a repeated measures study.
In order to quantify the spontaneous
locomotor activity (SLA), were used two 4x4
meters behavioral stalls with a smoked-glass
window each, directed towards the
observing room, and avoiding interaction
of the horses with the outside environment.
Each behavioral stall was equipped with four
pairs of photoelectric sensors (Banner
Engineering Corp. - Minneapolis, MN-
USA) that emitted infrared beams
composing nine virtual squares. An electric
pulse was created each time one beam was
interrupted. The number of pulses were
counted at five minute intervals and
recorded in a data logger (Data Logger,
Campbell Scientific, Inv. Logan, UT-USA)
connected to a computer.19 SLA was
calculated from data registered in the
computer as the mean of interruptions every
10 minutes.
Head ptosis (HP) was used to evaluate
the sedation intensity by quantifying the
distance between the lower lip and the floor
measured in centimeters, confronting the
lower lip with the metric length unit painted
on the walls of  the stalls.20 In the statistical
analysis these data were converted to
percentage relating the observed value at the
respective moment and the mean basal value
(measured before the drug administration).
At each observation moment, the
position of the horses in the stall was checked
in relation to the virtual squares composed
by the infrared beams referred above. This
could indicate if the horses were searching
for some kind of outside contact, as well as
the interference of the manipulation in their
behavior.
In the afternoon preceding the
experiments, horses were placed inside the
behavioral stalls (one per stall) receiving
grass hay and water ad libitum. On the
experiment day, the hay was removed
from the stalls at 6:30 am and at 7:00 am
the sensors were turned on and the basal
values for SLA were measured for one
hour.  During this period, HP was
measured at fifteen minute intervals.
For drug injection, the horses were
kept inside the stalls and handled in the
softest way,  in order to minimize
behavioral interferences. At 8:00 am,
romifidine (Sedivet – Boehringer De
Angeli Química e Farmacêutica Ltda. -
Itapecerica da Serra, SP-Brazil) (0.06mg/
kg) or amitraz (Amitraz - Laboratório
Sintesul SA. - Pelotas, RS-Brazil) emulsion
(0.1mg/kg or 0.4mg/kg) was injected in
the external jugular vein. Amitraz emulsion
was prepared as described by Farias 21 and
the applied doses were based on previous
studies with this emulsion on horses  22, 23.
Initially, HP was evaluated at ten
minute intervals (T10, T20 e T30), followed
by fifteen minute intervals (T45 e T60) for
the first hour and then at thirty minute
intervals (T90, T120, T150 e T180) until the
third observation hour. The same schedule
was applied to define the horse’s location
inside the stall. The SLA was measured for
6 hours (T10 a T360) using five minute
intervals. After the experimental period the
horses were removed from the stalls and
taken back to the pastures.
The HP and SLA data were analyzed
using the non-parametric Wilcoxon’s test for
repeated measures in order to compare each
observation moment to the basal values.
Comparisons among treatments were
carried out using a non-parametric
Friedman’s test for repeated measures,
followed by the Student-Newman-Keuls’
test (SNK). The results were considered
significantly different when P < 0.05. Data
concerning the location of the horses were
submitted to subjective analysis for
frequencies of occurrence.
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Results
Tables 1 and 2 show data related to
HP and SLA, and the comparisons between
the observation moments after drug
administration and basal values for each
treatment. Figure 1 show the comparison
among treatments for HP. Figure 2 show
the comparison for SLA between
observation moments among treatments
after drug administration and basal values
for each treatment.
Romifidine induced intense HP
(P<0.05) over 45 minutes; amitraz induced
HP (P<0.05) over 180 minutes for the higher
dose. The lower dose of amitraz produced
HP from 45 to 60 and from 120 to 150
minutes after its administration. During 20
minutes HP induced by romifidine or
amitraz 0.4mg/kg were greater than amitraz
0.1mg/kg (P<0.05). After 20 minutes, the
sedation caused by amitraz at the dose of
0.4mg/kg was greater than that of
romifidine or amitraz 0.1mg /Kg (P<0.05).
Discussion
Despite several authors’ statements
that amitraz is an alpha-2 agonist drug
12,13,14,17,18, there are no pharmacological
studies that establish its specificity to this
receptor. Thus, a clinical comparison
between amitraz and romifidine, which is a
potent alpha-2 agonist 24, 25, is proposed as
an efficient method to establish possibilities
of using amitraz as an intense and long lasting
Table 1 - Head ptosis (percentage from basal values) observed in horses treated with intravenous injection of
romifidine (0.06mg/kg) or amitraz (0.1 or 0.4mg/kg). Basal values were considerer 100%. T10 to T180
indicate checking at respective moments (in minutes) after drug administration. HP: head ptosis. RMF:
romifidine. AM 0.1: amitraz 0.1mg/kg. AM 0.4: amitraz 0.4mg/kg. Data presented as median, minimum
and maximum values. *: Significant differences when compared to basal values, Wilcoxon’s test (P<0,05).
Jaboticabal-SP, 2006
Table 2 - Spontaneous locomotor activity observed in horses treated with intravenous injection of romifidine
(0.06mg/kg) or amitraz (0.1 or 0.4mg/kg), presented as movements every 10 minutes, at each observation
moment. BASAL indicates checking before drug administration. T10 to T360 indicate checking at respective
moments (in minutes) after drug administration. SLA: spontaneous locomotor activity. RMF: romifidine.
AM 0.1: amitraz 0.1mg/kg. AM 0.4: amitraz 0.4mg/kg. Data presented as median, minimum (min) and
maximum (max) values. *: Significant differences when compared to basal values, Wilcoxon’s test
(P<0,05). Jaboticabal-SP, 2006
301
Braz. J. vet. Res. anim. Sci., São Paulo, v. 45, n. 4,  p. 298-304, 2008
Figure 1 - Head ptosis observed in horses treated with intravenous injection of romifidine (0.06mg/kg) or amitraz
(0.1 or 0.4mg/kg), presented as a percentage relation between the observed value of the distance between
the lower lip and the floor at the respective moment and the basal value. The arrow indicates the moment
of drug administration. Data presented as median. *: Significant differences when comparing amitraz
0.1mg/kg and amitraz 0.4mg/kg (SNK’s test; P<0.05). #: Significant differences when comparing amitraz
0.4mg/kg and romifidine (SNK’s test; P<0.05). D: Significant differences when comparing amitraz
0.1mg/kg and romifidine (SNK’s test; P<0.05). Jaboticabal-SP, 2006
Figure 2 - Spontaneous locomotor activity observed in horses treated with intravenous injection of romifidine
(0.06mg/kg) or amitraz (0.1 or 0.4mg/kg), presented as movements in 10 minutes, between each observation
moment. The arrow indicates the moment of drug administration. There were no differences among
treatments. Data presented as median. *: Significant differences when comparing to basal values, for
romifidine 0.06mg/Kg (Wilcoxon’s test; P<0.05). #: Significant differences when comparing to basal
values, for amitraz 0.1mg/Kg (Wilcoxon’s test; P<0.05). Jaboticabal-SP, 2006
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sedative for horses.
The comparison between the amitraz
0.1 and 0.4mg/kg shows stronger effects at
the higher dose. These dosages of amitraz,
prepared in the same emulsion, were
previously used 22 and showed similar dose-
dependent effects in horses.
Dimetilformamide 26, 27 and DMSO
28, 29, 30 are organic excipients used in amitraz
suspensions because of the low
hydrosolubility of amitraz, which also occurs
with other apolar substances.
Dimetilformamide or DMSO excipients
increase the plasmatic disposal of amitraz
and probably also its plasma availability 21.
It is believed that the lipid excipient
used in this research creates an emulsion that,
when in contact with blood, decreases the
plasmatic disposal of amitraz thereupon
injection. A first passage through the liver
would be needed in order to increase the
availability of  the drug. Thus the amitraz
levels available to interact with the
adrenoceptors in the central nervous system
would be smaller in the first half hour, which
explains its relatively long latency of sedative
effects. This could also explain the
lower sedative effect observed when
using the lipid excipient in the same dose
described with other excipients, as
the intravenous injections of amitraz 0.1mg/
kg diluted in dimetilformamide 18,
for example.
Although romifidine presented
sedation equivalent to that of amitraz
0.4mg/kg during the first 20 minutes, a
substantial and long lasting sedative effect
of  amitraz with this dosage was observed,
which remained until the end of the
observation time (180 minutes). This
suggests that the intensity of  amitraz sedation
is dose-dependent and that the lipid excipient
was determinant for the long lasting effect.
These results and the fact that the sedative
effect was more intense with amitraz at
0.4mg/kg than at 0.1mg/kg confirm what
was reported by Costa et al. 31, who
described the duration and intensity of the
effects of amitraz as dose-dependent.
Statistics shows that romifidine
reduced SLA (P<0.05) at 180 and 240
minutes, and amitraz 0.1mg/Kg had the
same effect from 45 to 60 minutes after it
administration, while amitraz 0.4mg/Kg did
not reduced SLA. These results are not
consistent with the observed for HP.
The large range observed in basal
values for all treatments may have covered
real effects, since the medians themselves
showed other tendencies.  Besides, it was
already described that romifidine indeed
induced ataxia in horses 10, 32, what would
result in reduced SLA. Harkins et al. 26
observed a reduction of  SLA of  horses for
120 minutes after intravenous injection of
amitraz. However, it must be also considered
that these authors used dimetilformamide as
excipient for amitraz and that it has distinct
pharmacological properties from the lipid
emulsion used in the present study.  Therefore,
it seems that the sample must be increased
for this kind of evaluation to be reliable in
this study.
Before the drugs administration, the
horses were mainly placed in front of the
observation window of  the stall; from 10
to 180 minutes after the administration of
drugs, they were mainly placed in front of
the door. This observation shows that,
although relatively isolated from the outside
environment, the horses kept on searching
for some kind of contact with the exterior
of  the stall even during the sedation periods.
Conclusion
The amitraz emulsion produced a
dose-dependent sedation for 180 minutes.
Romifidine at this dosage caused a substantial
sedation for 45 minutes. Comparing to
romifidine, the emulsion of amitraz induced
a more substantial sedation. At dosages and
dilution applied, amitraz is an effective
sedative for horses.
Acknowledgements
To Fundação de Amparo à
Pesquisa do Estado de São Paulo - FAPESP
(process number 02/13569-7).
303
Braz. J. vet. Res. anim. Sci., São Paulo, v. 45, n. 4,  p. 298-304, 2008
Comparação dos efeitos da romifidina e de uma emulsão de amitraz na
sedação e na atividade locomotora espontânea de eqüinos
Resumo
Os agonistas de receptores adrenérgicos do tipo alfa-2 amitraz (AM)
e romifidina (RMF) produzem efeito sedativo e reduzem a atividade
locomotora espontânea (ALE) em eqüinos. Compararam-se os efeitos
sedativos e comportamentais da injeção intravenosa de RMF (0,06mg/
kg) ou AM 0,1mg/kg (AM 0,1) ou 0,4mg/kg (AM 0,4) em cavalos.
RMF provocou ptose de cabeça (PC) por 45 minutos. O amitraz
provocou PC entre 45 e 60 e entre 120 e 150 minutos com a dose
menor, e por 180 minutos com a dose maior. Os dados relacionados
à ALE não foram conclusivos.  RMF ou AM 0,4 causaram sedação
mais intensa que AM 0,1 até 20 minutos. Após 20 minutos, a sedação
provocada pelo AM 0,4 foi mais intensa que para a RMF ou o AM 0,1.
A romifidina causou sedação por 45 minutos. A emulsão de amitraz
provocou sedação dose-dependente por 180 minutos. Em relação à
romifidina, o amitraz produziu uma sedação mais consistente. Nas
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